Adamax: what the studies show, status and safety
Summary
Adamax is sold as a nootropic peptide, but it has never been studied. Six literature and substance databases were searched on 6 September 2026 and held nothing about it, and the sellers say the same in their own words. Even its structure is unsettled. No health authority anywhere has approved it, so it is banned in sport at all times.
Key findings at a glance
- Not one scientific paper. Six databases were searched on 6 September 2026. None of them holds anything about this substance [1], [2], [3], [4], [5], [6].
- The 39 PubMed hits are a computing method. Every one of them was checked. All concern Adamax as a variant of the Adam optimiser used to train machine-learning models, not a chemical [1].
- The same searches do find Semax. Semax, the peptide Adamax is said to be built from, returns 231 records in the same query run. The empty result for Adamax is therefore not a fault in the search [1].
- The seller contradicts itself about the molecule. One product page gives both the formula C44H61N11O13S and a mass of 1,032.3 g/mol. That formula works out to 984.1 g/mol, about 48 units lighter, so the two figures cannot describe the same substance [7], [8].
- No identifier of any kind. There is no PubChem entry, no code with the American regulator and no patent. The product page states the CAS registry number as "N/A" itself [4], [6], [8], [9].
- The sellers admit there is no research. The person credited with creating it is quoted saying it was made with no clinical research "or any research of any kind". A Russian shop writes that it remains uninvestigated [10], [11].
- Banned in sport around the clock. Category S0 covers substances that no health authority has approved for people, which covers Adamax without any need to name it [12].
What it is
Adamax is a trade article, sold in vials by a handful of research-chemical shops. Everything said about it in public was written by a seller, or by someone repeating one. The name is a coinage rather than a scientific term: "Ada-" from adamantane, a cage-shaped carbon structure, and "-max" from maximal [11].
There is no laboratory behind it. Sellers and scene sources agree in attributing the substance to Ceretropic, a research-chemical shop in Mexico that shut down permanently in 2018 [10], [11]. No university group, no institute and no company pipeline has ever claimed it, and no paper introduced it.
Quick facts
| Field | Value | Ref |
|---|---|---|
| What it is sold as | A research chemical with no scientific or regulatory standing | [1], [5] |
| Origin of the name | A seller's coinage from adamantane and maximal | [11] |
| Structure | Not established. The same shop publishes two different sequences | [8], [11] |
| Formula and mass | No verified value. One page gives C44H61N11O13S and 1,032.3 g/mol, which do not match | [7], [8] |
| CAS registry number | None. The product page states "N/A" | [8] |
| PubChem entry | None. Seven different spellings were tried and all returned not found | [4] |
| Code with the American regulator | None | [9] |
| Patent | None | [6] |
| How long it lasts in the body | No published value | [1] |
| Registered studies in people | None | [5] |
| Approval status | Approved nowhere, for nothing | [9], [13] |
| Attributed to | Ceretropic, a shop that closed in 2018 | [10], [11] |
How it works
Nothing is known about how Adamax behaves in a living body, because nobody has ever measured it. What circulates instead are claims, and it is worth separating what sellers say from what has actually been shown.
Sellers make four main claims. Each is followed here by what the evidence for that claim actually is.
- "It is Semax that lasts longer." Blocking both ends of a peptide chain does slow its breakdown, and that has been examined for acetylated Semax [14], [15]. It has never been examined for Adamax.
- "The adamantane part carries it into the brain." This principle was published for a different peptide, P021, where an adamantane group improved delivery to the brain in mice [16]. P021 has another sequence and says nothing about Adamax.
- "It releases amantadine in the body." This appears in a shop's own text, phrased there as a possibility. There is no metabolism experiment behind it [11].
- "It raises BDNF, a growth factor in the brain." This comes from an English-language scene article and has never been measured for Adamax. It is a Semax finding transferred to a different molecule [10].
The common thread is that every mechanism attributed to Adamax was borrowed from another substance. Such reasoning by analogy is not evidence. Small changes to a peptide alter how it binds, how quickly it breaks down and where it ends up in the body.
There is a further problem underneath all of this. Even the analogy rests on a structure that is not confirmed, so it is not clear which molecule the reasoning is supposed to apply to [7].
What the trials found
Nothing, because there are no trials. There is no registered study in people, no published animal experiment and no cell work. Nobody who is not also selling the substance has ever analysed it [1], [2], [5].
How that was checked
The absence was tested rather than assumed, and each search was run with a control that was known to work.
- PubMed. The term Adamax returns 39 records, and all 39 were opened individually. Every one is about a computing method. Searches pairing Adamax with nootropic, cognitive or peptide, and searches for adamantyl combined with Semax, return nothing [1].
- Europe PMC. Eighteen hits, all of them machine-learning papers. The Russian spelling returns nothing [2].
- Crossref. No entry for the substance across four differently phrased searches [3].
- PubChem. Seven spellings of the name, each returning not found. Semax and N-acetyl semax amidate resolve normally in the same run [4].
- ClinicalTrials.gov. No study, finished, running or planned [5].
- Google Patents. No patent. For something marketed as a product innovation, that is telling in itself [6].
What is still unknown
Almost everything. Nobody has measured how much reaches the bloodstream, how long it stays there or whether it enters the brain. Nobody has measured how it is broken down, what it does to organs over time, or whether it does anything at all.
What exists instead
Two published lines of work are regularly cited as though they were about Adamax. Neither is. The P021 papers describe a different peptide with a different sequence [16], [17]. The Semax papers describe the peptide Adamax is merely said to be derived from [14], [15].
Side effects and safety
No side-effect profile exists, and that is not the same as being well tolerated. Nobody has taken Adamax in a study, so nothing has ever been recorded, counted or reported. The absence of reported harm here reflects an absence of looking [1], [5].
There is a second, unusual problem. With most unstudied substances the molecule is at least known. Here it is not. The same shop gives one sequence in its article and another on its product page.
Its printed formula also rules out the adamantane group it describes. The acetylated Semax backbone already accounts for 39 carbon atoms, and an adamantane cage adds ten more. The formula allows only 44 [7], [8], [11].
Without a settled identity, no safety statement is possible in either direction. Nobody can say what is in the vial, so nobody can say what it would do.
The closest thing to an official assessment concerns the parent substance. Ahead of a July 2026 meeting, the American regulator wrote that it could not rule out immune reactions to Semax. It lacked information on impurities and on whether the peptide clumps together.
It also found there was too little clinical information to describe a safety profile for Semax at all [18]. That assessment is about Semax. For Adamax there is none.
What is missing
- No study in people: no safety data, no tolerated dose, no measurement of uptake or clearance.
- No animal study and no toxicology work of any kind.
- No laboratory data: no receptor binding, no cell experiments, no stability measurement.
- No settled structure, and no independent chemical analysis from a source that is not selling it.
- No information on impurities, endotoxins or actual peptide content from independent testing.
- No manufacturer liability and no pharmaceutical quality control, since the shop credited with creating it closed in 2018 [10].
Why this page lists no doses
Every dose in this register comes from a published study, with the population, the length of treatment and the source attached. For Adamax there is no such study, so there is no dose to report [5].
That is a different situation from an approved medicine, where doses are left out because prescribing belongs to a doctor. Here the numbers simply do not exist.
The milligram figures and schedules on sales pages were never measured. They are sales copy. One Russian page does list sources for its figures, but three of the journals it names do not exist in the Crossref journal register [3], [19].
Development and approval status
A trade article, never a development programme
- before 2018Ceretropic sells the peptideA research-chemical shop in Mexico, credited as the origin, ref [10]
- 2018Ceretropic closes permanentlyOther shops carry on selling under the same name, refs [10], [11]
- 2025A review maps the grey marketIt lists Semax, Selank and two adamantane compounds, but not Adamax, ref [20]
- July 2026The American regulator reviews SemaxAdamax does not appear in the meeting documents at all, ref [18]
- 6 September 2026Six databases searchedNo paper, no patent, no substance record, no trial, refs [1] to [6]
Adamax is not in development, early or otherwise. There is no sponsor, no institute and no programme, and that sets it apart even from substances described as preclinical. Those at least have a published animal experiment behind them. Here there is no documented experiment at all.
| Market | Status | Note | Ref |
|---|---|---|---|
| United States | Not approved | No substance record; absent from the July 2026 compounding review | [9], [18] |
| European Union | Not approved | No application, and no company left to file one | [13] |
| Germany | Not approved | Follows the European route | [13] |
| United Kingdom | Not approved | No marketing authorisation | [13] |
| Australia | Not approved | Not in the register of medicines, and not named in the Poisons Standard | [21] |
| Canada | Not approved | The ingredient database returns nothing | [22] |
| Switzerland | Not approved | No marketing authorisation | [13] |
| Russia | Not approved | Sold as a research substance only | [11], [19] |
Two entries need care. Not being named in the Australian Poisons Standard is not permission, because unapproved medicines need approval regardless [21].
The Russian entry is often blurred as well. Sellers report that the parent substance Semax is registered as a medicine in Russia, but nobody claims any registration for Adamax [11], [19]. Every register search behind this table was run on 6 September 2026.
Anti-doping
Adamax is banned at all times, in and out of competition. Category S0 of the 2026 Prohibited List covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use" [12].
The substance is not printed on the list by name, and neither is Semax. That absence is the opposite of a loophole. This part of the list is written openly on purpose, to catch exactly those substances no authority has approved [12].
A 2025 review of grey-market cognitive substances lists Semax and Selank as cases with an unclear status. Adamax does not appear in it at all [20].
There is also no published test for it. No reference material and no laboratory method exists, so a result could not be traced back to the substance itself [1], [23]. Further detail is in the overview of peptides banned in sport.
Compared with related peptides
Searches run on 6 September 2026 in the same query run. The 39 records returned for Adamax were checked individually and all concern a computing method, leaving zero about the substance. Sources [1], [24].
| Substance | Records on PubMed, 6 September 2026 | Database entry | What it is |
|---|---|---|---|
| Semax | 231 [1] | PubChem CID 9811102 [25] | A seven-part peptide from Russian institute research, sold and studied for decades |
| Selank | 136 [24] | PubChem CID 11765600 [26] | Named in a 2025 review of grey-market cognitive substances [20] |
| N-acetyl semax amidate | 0 under that trade name [1] | PubChem CID 172638603 [27] | A distinct compound with both ends blocked, carrying no adamantane |
| Adamax | 0 about the substance [1] | None [4] | Sold as a peptide; structure disputed, origin a closed shop |
The comparison is not about strength or quality. It shows what a documented substance looks like next to one that exists only in commerce. Semax has a formula, a mass, a database record and a body of literature that anyone can check. Adamax has a name and a price.
The nearest confusion is worth spelling out. N-acetyl semax amidate is a real, separately recorded compound, and it carries no adamantane group [27]. Sellers describe Adamax as exactly that compound with such a group added. The two names therefore do not refer to the same molecule, however often shops list them side by side.
Common misconceptions
- "Adamax is a studied nootropic." No paper exists. The person credited with creating it said it was made with no research of any kind, and a Russian shop writes that it remains uninvestigated [10], [11].
- "PubMed lists 39 studies on it." Those 39 records are about a machine-learning method that shares the name. Quoting the count as evidence means quoting computer science as pharmacology [1].
- "Adamax is Semax, only stronger." Semax is a separate peptide with its own record and its own literature [1], [25]. Even on the sellers' own description, Adamax would be a different molecule with different behaviour.
- "Adamax and N-acetyl semax amidate are the same." They are not. The latter has its own database entry and no adamantane group [27].
- "The A in the sequence means adamantane." In the standard one-letter code for peptides, A means alanine. That ambiguity is exactly where the contradictory formula comes from, and the two readings differ by about 48 mass units [7].
- "It is a metabolism peptide for weight loss." One sales page says so, another calls the same substance a brain drug, and both cannot be right. Three of the journals cited for the weight figures do not exist [3], [19].
- "It comes from Russian institute research, like Semax." It does not. It is attributed to a Mexican research-chemical shop that closed in 2018. The Russian connection comes from who sells it today [10], [11].
- "A purity figure of 97 per cent shows the product is good." Without a settled structure and independent testing, it is unclear what the figure refers to. It is the seller's own statement [8].
Frequently asked questions
Are there any studies on Adamax?
No, not one. Searches of PubMed, Europe PMC, Crossref, PubChem, ClinicalTrials.gov and Google Patents on 6 September 2026 returned nothing about the substance. The same searches find hundreds of papers on the related peptide Semax, so this is a real absence rather than a broken search.
Why does PubMed show 39 hits for Adamax?
Because Adamax is also the name of a method used in computing, a variant of the Adam optimiser used to train machine-learning models. All 39 records were checked one by one, and every single one is about image analysis, tumour classification or network security. None is about a substance.
What exactly is Adamax made of?
Nobody outside the shops selling it can say. One seller describes it as the peptide Semax with a cage-shaped carbon group called adamantane attached. The same seller then publishes two different sequences on two different pages. The formula and the molecular mass on its product page do not match each other either.
Is Adamax the same thing as Semax?
No. Semax is a separate, well-documented peptide with 231 entries in the PubMed literature database and its own PubChem record. Adamax has neither. Even if the claimed structure were correct, it would be a different molecule, so findings about Semax say nothing about Adamax.
Who invented Adamax?
No university or company laboratory did. Sellers and scene sources agree in attributing it to Ceretropic, a research-chemical shop based in Mexico that closed permanently in 2018. Its founder is quoted as saying the peptide was developed with no clinical research and no research of any kind.
Is Adamax approved as a medicine anywhere?
No, in no country and for no condition. It has no approval, no pending application, no registered clinical trial and no substance record with any regulator. Searches of the American, Canadian and Australian databases on 6 September 2026 all came back empty.
Is Adamax banned in sport?
Yes, at all times, in and out of competition. Category S0 of the 2026 Prohibited List covers any drug-like substance that no health authority has currently approved for use in people. Adamax is not printed on the list by name, and that absence is not a loophole.
Does Adamax help with weight loss?
There is no evidence of that, or of anything else. One Russian sales page describes Adamax as a metabolism peptide and quotes exact figures from animal experiments, while another describes the same substance as a brain drug. Three of the journals cited for those figures do not exist.
Is Adamax dangerous?
That question cannot be answered, which is itself the problem. There is no study in people, no animal study and no toxicology work. Because the identity of the molecule in the vial is not settled either, no safety statement is possible in either direction.
Why does this page list no doses for Adamax?
Because there are no study doses to report. Doses in this register come from published studies, and no study of Adamax exists. The milligram figures and schedules on sales pages come from sales copy, not from any measurement, so reproducing them would lend them a weight they have not earned.
Sources
- PubMed, NCBI E-utilities. Searches for "Adamax" (39 records, each checked by summary and all concerning the Adam optimiser in machine learning), "Adamax AND nootropic", "Adamax AND cognitive", "adamantyl AND Semax", "adamantane AND Semax", "N-adamantyl AND Semax", "adamantylcarbonyl AND ACTH", "N-acetyl semax amidate" (0 records each) and the control search "semax" (231 records). Retrieved 6 September 2026. https://pubmed.ncbi.nlm.nih.gov/?term=Adamax
- Europe PMC, REST search. Queries "Adamax AND (peptide OR nootropic OR neuropeptide OR Semax)" (18 records, all machine learning), TITLE:"Adamax" (1 record, machine learning) and "адамакс" (0 records). Retrieved 6 September 2026. https://www.ebi.ac.uk/europepmc/webservices/rest/search
- Crossref, works API. Bibliographic queries for "Adamax peptide", "Adamax nootropic peptide", "Adamax Semax analogue" and "adamantyl Semax"; no record about the substance. Journal-title checks for three journals cited on a Russian sales page returned no such journals. Retrieved 6 September 2026. https://api.crossref.org/works
- PubChem, PUG-REST name resolution. Seven spellings including "Adamax", "Adamax peptide", "adamantyl-Semax" and "adamantylcarbonyl-Met-Glu-His-Phe-Pro-Gly-Pro", each returning HTTP 404 not found, while Semax and N-acetyl semax amidate resolved in the same run. Retrieved 6 September 2026. https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/Adamax/property/MolecularFormula/JSON
- ClinicalTrials.gov, API v2. Queries for "Adamax", "adamantyl semax", "Semax", "N-acetyl semax amidate" and "адамакс"; each returned a total count of zero. Retrieved 6 September 2026. https://clinicaltrials.gov/api/v2/studies
- Google Patents, query endpoint. Searches for "Ac-MEHFPGP" and "Adamax peptide nootropic" returned nothing; "adamantane semax peptide" returned three unrelated patents. Retrieved 6 September 2026. https://patents.google.com/
- myPeptides Research & Editing. Recalculation of the seller's structural figures, 6 September 2026. The method was validated first against PubChem CID 172638603. The stated formula C44H61N11O13S corresponds to 984.1 g/mol and matches the reading in which the letter A is alanine; the stated mass of 1,032.3 g/mol matches the adamantane-bearing structure C50H69N11O11S at 1,032.2 g/mol. Reference values from PubChem CID 9811102, CID 172638603 and CID 365221.
- Product page for Adamax at a research-chemical seller, retrieved 6 September 2026. States "CAS No.: N/A", purity above 97 per cent, a freeze-dried form with mannitol, the sequence Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Adam-NH2, a molecular mass of 1,032.3 and the formula C44H61N11O13S1. Seller source, cited as evidence of what is claimed. Not linked.
- openFDA. Queries of drug/label.json, drug/ndc.json and drug/drugsfda.json for Adamax as a substance or active ingredient; each returned not found. Retrieved 6 September 2026. https://api.fda.gov/drug/label.json
- Scene article "Adamax & P21: Two New Nootropic Peptides To Watch Closely", retrieved 6 September 2026. Attributes the peptide to Ceretropic, a Mexico-based seller that shut down in 2018, states that the structure was assembled from forum threads, and quotes its originator: "This is a brand new peptide we developed with no human clinical research, or any research of any kind." Scene source. Not linked.
- Seller article "Adamax — новая модификация Semax", retrieved 6 September 2026. Gives a sequence containing an extra glycine residue, explains the name as adamantane plus maximal, attributes the substance to Ceretropic, raises the possibility of amantadine being released, and states that "Adamax до сих пор не исследован" — Adamax has not been investigated to this day. Seller source. Not linked.
- World Anti-Doping Agency. The 2026 Prohibited List, in force from 1 January 2026, section S0. Full-text checks of the 2025 and 2026 lists for "adamax", "adamant", "semax" and "selank" returned no match. Retrieved 6 September 2026. https://www.wada-ama.org/en/prohibited-list
- Register searches for the European Union, Germany, the United Kingdom and Switzerland, 6 September 2026. No marketing authorisation, no application and no registered clinical trial was identified. The European Medicines Agency search page returned an authorisation error during this check, so the European finding rests on the absence of any entry in every other register searched and on the absence of any clinical trial. https://www.ema.europa.eu/en/medicines
- Shevchenko KV et al. (2013). Stability of Semax acetyl to proteolysis in various biological media. Doklady Biological Sciences 449:110-112. PMID 23652441. DOI 10.1134/S0012496613020166. No abstract is held in PubMed, so the figures quoted from it by sellers could not be checked against the original.
- Magrì A et al. (2016). Influence of the N-terminus acetylation of Semax on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry 164:59-69. PMID 27586814. DOI 10.1016/j.jinorgbio.2016.08.013
- Li B et al. (2010). Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Letters 584(15):3359-3365. PMID 20600002. DOI 10.1016/j.febslet.2010.06.025. Describes P021, a different peptide, written in the abstract as Ac-DGGLAG-NH2 using the same ambiguous one-letter placeholder.
- Chohan MO et al. (2011). Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiology of Aging 32(8):1420-1434. PMID 19767127. DOI 10.1016/j.neurobiolaging.2009.08.008
- FDA (2026). Briefing document: evaluation of semax-related bulk drug substances for inclusion on the 503A bulks list. Pharmacy Compounding Advisory Committee, meeting of 23 to 24 July 2026, document dated 11 May 2026. States that "we cannot rule out the potential for immunogenicity associated with these impurities and peptide related aggregates" and that "there is insufficient clinical information to characterize the safety profile of semax (free base) or semax acetate". A full-text search of this document and of the combined meeting package for "adamax" returned no match. Retrieved 6 September 2026. https://www.fda.gov/media/193348/download
- Russian sales page for Adamax, retrieved 6 September 2026. Describes the same substance as a metabolism peptide, gives figures from cell and animal experiments, and states that it has no registered status as a medicine. Of the five sources it cites, three journals do not exist in the Crossref journal register, one citation cannot be resolved in PubMed and one is an internal company document. Seller source. Not linked.
- Pokrywka A et al. (2025). "Brain doping" substances: prohibited or not in sports? Biology of Sport 42(4):189-201. PMID 41048238. DOI 10.5114/biolsport.2025.150047. PMCID PMC12492343. The market analysis found 120 synthetic substances with possible pro-cognitive effects, 45 of them of unclear status; Table 6 lists Semax, Selank and two adamantane compounds among them. A full-text check found no mention of Adamax.
- Poisons Standard (SUSMP) 2026, Australia. Full-text search for "adamax" and "semax" returned no match, and no entry exists in the register of therapeutic goods. Absence from the Poisons Standard does not amount to permission. Retrieved 6 September 2026. https://www.tga.gov.au/resources/artg
- Health Canada. Drug Product Database API, active-ingredient queries for "Adamax", "ADAMAX" and "Semax"; each returned an empty list. Retrieved 6 September 2026. https://health-products.canada.ca/api/drug/activeingredient/
- Anti-doping substance documents of the Voluntary Anti-Doping Association and the NCAA, full-text checks for "adamax" and "semax" on 6 September 2026; no match.
- PubMed, NCBI E-utilities. Control search for "selank", 136 records. Retrieved 6 September 2026. https://pubmed.ncbi.nlm.nih.gov/?term=selank
- PubChem. Compound CID 9811102, Semax, C37H51N9O10S, 813.9 g/mol. Retrieved 6 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/9811102
- PubChem. Compound CID 11765600, Selank, C33H57N11O9, 751.9 g/mol. Retrieved 6 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/11765600
- PubChem. Compound CID 172638603, N-acetyl semax amidate, C39H54N10O10S, 855.0 g/mol; carries no adamantane group. Retrieved 6 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/172638603
Cite this page
The searches behind this page were run on 6 September 2026. For a substance with no scientific record at all, the date on which those searches came back empty is part of the finding itself.
myPeptides Research & Editing. (2026). Adamax: what the studies show, status and safety. Version 1.0, 6 September 2026. myPeptides Peptide Register. Retrieved from https://mypep.app/peptides/adamax
How pages in this register are compiled and graded is described under methodology; the full register is at peptides.
| Version | Date | Change |
|---|---|---|
| 1.0 | 2026-09-06 | Initial publication |
Last verified: 6 September 2026. Next review: on the appearance of any peer-reviewed publication, patent or database entry naming this substance, or on any change in the anti-doping classification.